Peptide vaccines for the treatment of glioblastoma

Glioblastoma multiforme (GBM) is an extremely malignant brain tumor for which current therapies do little to remedy. Despite aggressive treatment with surgery, radiation therapy, and chemotherapy, tumors inevitably recur as a direct consequence of the infiltrative nature of GBM. The poor prognosis o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2015-07, Vol.123 (3), p.433-440
Main Authors: Swartz, Adam M., Batich, Kristen A., Fecci, Peter E., Sampson, John H.
Format: Article
Language:English
Subjects:
Brain Neoplasms - immunology
Brain Neoplasms - therapy
Editors' Invited Manuscript
Glioblastoma - immunology
Glioblastoma - therapy
Humans
Medicine
Medicine & Public Health
Neurology
Oncology
Vaccines, Subunit - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma multiforme (GBM) is an extremely malignant brain tumor for which current therapies do little to remedy. Despite aggressive treatment with surgery, radiation therapy, and chemotherapy, tumors inevitably recur as a direct consequence of the infiltrative nature of GBM. The poor prognosis of patients with GBM underscores the clear and urgent need for more precise and potent therapies. Immunotherapy is emerging as a promising means to treat GBM based on the immune system’s capacity to mediate tumor-specific cytotoxicity. In this review, we will discuss the use of peptide vaccines for the treatment of GBM. The simplicity of peptide vaccines and their ability to elicit tumor antigen-specific immune responses make them an invaluable tool for the study of brain tumor immunotherapy.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-014-1676-y